{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:26:47Z","timestamp":1777364807839,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Travel Medicine and Infectious Disease"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.tmaid.2022.102520","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T20:09:32Z","timestamp":1670962172000},"page":"102520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["On the potential for discontinuing atovaquone-proguanil (AP) ad-hoc post-exposure and other abbreviated AP-regimens: Pharmacology, pharmacokinetics and perspectives"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2691-8130","authenticated-orcid":false,"given":"Jenny L.","family":"Schnyder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna K.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel B.","family":"Bache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinier M.","family":"van Hest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Schlagenhauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Borrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hanscheid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-1099","authenticated-orcid":false,"given":"Martin P.","family":"Grobusch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.tmaid.2022.102520_bib1","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/jac\/dkm337","article-title":"A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria","volume":"60","author":"Nakato","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.tmaid.2022.102520_bib2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0035-9203(98)90772-6","article-title":"Challenges in the development of antimalarial drugs with causal prophylactic activity","volume":"92","author":"Chulay","year":"1998","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.tmaid.2022.102520_bib3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0035-9203(46)90052-1","article-title":"Researches on paludrine (M. 4888) in malaria. An experimental investigation undertaken by the LHQ medical research unit (AIF), Cairns, Australia","volume":"40","author":"Fairley","year":"1946","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"4","key":"10.1016\/j.tmaid.2022.102520_bib4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0035-9203(01)90206-8","article-title":"Causal prophylactic efficacy of atovaquone-proguanil (MalaroneTM) in a human challenge model","volume":"95","author":"Berman","year":"2001","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"6","key":"10.1016\/j.tmaid.2022.102520_bib5","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0035-9203(91)90429-3","article-title":"Activity of dihydrofolate reductase inhibitors on the hepatic stages of Plasmodium yoelii yoelii in vitro","volume":"85","author":"Eriksson","year":"1991","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"5","key":"10.1016\/j.tmaid.2022.102520_bib6","doi-asserted-by":"crossref","first-page":"831","DOI":"10.4269\/ajtmh.1999.60.831","article-title":"Prophylactic activity of atovaquone against Plasmodium falciparum in humans","volume":"60","author":"Shapiro","year":"1999","journal-title":"Am J Trop Med Hyg"},{"issue":"4593","key":"10.1016\/j.tmaid.2022.102520_bib7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/bmj.1.4593.88","article-title":"\u201cPaludrine\u201d(Proguanil) in prophylaxis and treatment of malaria","volume":"1","author":"Covell","year":"1949","journal-title":"Br Med J"},{"key":"10.1016\/j.tmaid.2022.102520_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2019.101527","article-title":"Atovaquone\/proguanil for malaria chemoprophylaxis - could a difference in susceptibility during hepatic development explain the need to continue drug intake for 7 days post-exposure?","volume":"33","author":"Hanscheid","year":"2020","journal-title":"Trav Med Infect Dis"},{"key":"10.1016\/j.tmaid.2022.102520_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.tmaid.2017.12.005","article-title":"Abbreviated atovaquone-proguanil prophylaxis regimens in travellers after leaving malaria-endemic areas: a systematic review","volume":"21","author":"Savelkoel","year":"2018","journal-title":"Trav Med Infect Dis"},{"issue":"2","key":"10.1016\/j.tmaid.2022.102520_bib10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/jtm.12100","article-title":"Malaria chemoprophylaxis with atovaquone-proguanil: is a shorter regimen fully protective?","volume":"21","author":"Grobusch","year":"2014","journal-title":"J Trav Med"},{"issue":"2","key":"10.1016\/j.tmaid.2022.102520_bib11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/jtm.12088","article-title":"Effectiveness of short prophylactic course of atovaquone-proguanil in travelers to sub-saharan Africa","volume":"21","author":"Leshem","year":"2014","journal-title":"J Trav Med"},{"key":"10.1016\/j.tmaid.2022.102520_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2022.102365","article-title":"Discontinuing atovaquone\/proguanil prophylaxis ad-hoc post-exposure and during-travel dose-sparing prophylactic regimens against P. falciparum malaria: an update with pointers for future research","author":"Schnyder","year":"2022","journal-title":"Trav Med Infect Dis"},{"issue":"2","key":"10.1016\/j.tmaid.2022.102520_bib13","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/cid\/cir770","article-title":"Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model","volume":"54","author":"Deye","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"7618","key":"10.1016\/j.tmaid.2022.102520_bib14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nature18280","article-title":"Correction: a novel multiple-stage antimalarial agent that inhibits protein synthesis","volume":"537","author":"Baraga\u00f1a","year":"2016","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.tmaid.2022.102520_bib15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acsinfecdis.5b00143","article-title":"High-throughput luciferase-based assay for the discovery of therapeutics that prevent malaria","volume":"2","author":"Swann","year":"2016","journal-title":"ACS Infect Dis"},{"issue":"5","key":"10.1016\/j.tmaid.2022.102520_bib16","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0009-9236(97)90132-6","article-title":"Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum","volume":"61","author":"Hussein","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.tmaid.2022.102520_bib17","first-page":"S1471","article-title":"In vitro models for human malaria: targeting the liver stage","author":"Valenciano","year":"2022","journal-title":"Trends Parasitol"},{"issue":"11","key":"10.1016\/j.tmaid.2022.102520_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007881","article-title":"Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging","volume":"4","author":"Ploemen","year":"2009","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.tmaid.2022.102520_bib19","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1128\/AAC.42.5.1293","article-title":"Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial","volume":"42","author":"Brueckner","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.tmaid.2022.102520_bib20","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/AAC.00354-09","article-title":"Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects","volume":"54","author":"Nasveld","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.tmaid.2022.102520_bib21","first-page":"391","article-title":"The antimalarial action of primaquine against the blood and tissue stages of falciparum malaria (Panama, PF-6 strain)","volume":"46","author":"Arnold","year":"1955","journal-title":"J Lab Clin Med"},{"issue":"6","key":"10.1016\/j.tmaid.2022.102520_bib22","doi-asserted-by":"crossref","first-page":"693","DOI":"10.4269\/ajtmh.1967.16.693","article-title":"Effects of pyrimethamine, chlorguanide, and primaquine against exoerythrocytic forms of a strain of chloroquineresistant Plasmodium falciparum from Thailand","volume":"16","author":"Powell","year":"1967","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"10.1016\/j.tmaid.2022.102520_bib23","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1086\/313527","article-title":"Primaquine as prophylaxis for malaria for nonimmune travelers: a comparison with mefloquine and doxycycline","volume":"29","author":"Schwartz","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.tmaid.2022.102520_bib24","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/cid\/cix1077","article-title":"Vivax malaria chemoprophylaxis: the role of atovaquone-proguanil compared to other options","volume":"66","author":"Meltzer","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tmaid.2022.102520_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.92587","article-title":"Assessing drug efficacy against Plasmodium falciparum liver stages in vivo","volume":"3","author":"Flannery","year":"2018","journal-title":"JCI insight"},{"key":"10.1016\/j.tmaid.2022.102520_bib26","series-title":"Guidelines for the treatment of malaria","year":"2015"},{"issue":"4","key":"10.1016\/j.tmaid.2022.102520_bib27","doi-asserted-by":"crossref","first-page":"294","DOI":"10.7326\/0003-4819-120-4-199402150-00006","article-title":"Failure of doxycycline as a causal prophylactic agent against Plasmodium falciparum malaria in healthy nonimmune volunteers","volume":"120","author":"Shmuklarsky","year":"1994","journal-title":"Ann Intern Med"},{"issue":"20","key":"10.1016\/j.tmaid.2022.102520_bib28","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.297.20.2251","article-title":"Controversies and misconceptions in malaria chemoprophylaxis for travelers","volume":"297","author":"Chen","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.tmaid.2022.102520_bib29","series-title":"Atovaquone. Kucers' the use of antibiotics","first-page":"3117","author":"Redmond","year":"2017"},{"key":"10.1016\/j.tmaid.2022.102520_bib30","series-title":"Proguanil and chlorproguanil. Kucers' the use of antibiotics","first-page":"3127","author":"Davis","year":"2017"},{"issue":"6","key":"10.1016\/j.tmaid.2022.102520_bib31","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1128\/AAC.43.6.1334","article-title":"A mechanism for the synergistic antimalarial action of atovaquone and proguanil","volume":"43","author":"Srivastava","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.tmaid.2022.102520_bib32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2125.1994.tb04232.x","article-title":"Examination of some factors responsible for a food\u2010induced increase in absorption of atovaquone","volume":"37","author":"Rolan","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.tmaid.2022.102520_bib33","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1093\/jtm\/6.suppl.S13","article-title":"Clinical pharmacology of atovaquone and proguanil hydrochloride","volume":"6","author":"Beerahee","year":"1999","journal-title":"J Trav Med"},{"issue":"10","key":"10.1016\/j.tmaid.2022.102520_bib34","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1128\/AAC.49.10.4421-4422.2005","article-title":"Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration","volume":"49","author":"Edstein","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.tmaid.2022.102520_bib35","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1365-2125.1996.tb00114.x","article-title":"Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone","volume":"42","author":"Hussein","year":"1996","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.tmaid.2022.102520_bib36","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2125.1990.tb03818.x","article-title":"The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism","volume":"30","author":"Helsby","year":"1990","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.tmaid.2022.102520_bib37","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/infdis\/163.4.843","article-title":"Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men","volume":"163","author":"Hughes","year":"1991","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.tmaid.2022.102520_bib38","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1128\/AAC.40.3.556","article-title":"Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients","volume":"40","author":"Dixon","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"7556","key":"10.1016\/j.tmaid.2022.102520_bib39","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14451","article-title":"A novel multiple-stage antimalarial agent that inhibits protein synthesis","volume":"522","author":"Baraga\u00f1a","year":"2015","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.tmaid.2022.102520_bib40","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1128\/AAC.01685-15","article-title":"In vitro analysis of the interaction between atovaquone and proguanil against liver stage malaria parasites","volume":"60","author":"Barata","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tmaid.2022.102520_bib41","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jtm\/tay156","article-title":"Further observation of travellers taking twice-weekly atovaquone-proguanil prophylaxis in sub-Saharan Africa","volume":"26","author":"Biber","year":"2019","journal-title":"J Trav Med"},{"key":"10.1016\/j.tmaid.2022.102520_bib42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jtm\/taw064","article-title":"Effectiveness of twice a week prophylaxis with atovaquone-proguanil (Malarone\u00ae) in long-term travellers to West Africa","volume":"23","author":"Lachish","year":"2016","journal-title":"J Trav Med"},{"issue":"1","key":"10.1016\/j.tmaid.2022.102520_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-021-06953-4","article-title":"Reproducibility of malaria sporozoite challenge model in humans for evaluating efficacy of vaccines and drugs: a systematic review","volume":"21","author":"Shibeshi","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"7","key":"10.1016\/j.tmaid.2022.102520_bib44","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1473-3099(15)00068-7","article-title":"Design, recruitment, and microbiological considerations in human challenge studies","volume":"15","author":"Darton","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"47","key":"10.1016\/j.tmaid.2022.102520_bib45","doi-asserted-by":"crossref","first-page":"E1214","DOI":"10.1073\/pnas.1112037108","article-title":"Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue","volume":"108","author":"Adjalley","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.tmaid.2022.102520_bib46","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/00034983.1999.11813408","article-title":"In-vitro activity of primaquine against the asexual blood stages of Plasmodium falciparum","volume":"93","author":"Basco","year":"1999","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.tmaid.2022.102520_bib47","author":"Anderson"},{"issue":"12","key":"10.1016\/j.tmaid.2022.102520_bib48","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1128\/AAC.00937-10","article-title":"Mitochondrial electron transport inhibition and viability of intraerythrocytic Plasmodium falciparum","volume":"54","author":"Painter","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.tmaid.2022.102520_bib49","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.chembiol.2019.11.009","article-title":"Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery","volume":"27","author":"Murithi","year":"2020","journal-title":"Cell chemical biology"}],"container-title":["Travel Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477893922002666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477893922002666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:09:20Z","timestamp":1761487760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1477893922002666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":49,"alternative-id":["S1477893922002666"],"URL":"https:\/\/doi.org\/10.1016\/j.tmaid.2022.102520","relation":{},"ISSN":["1477-8939"],"issn-type":[{"value":"1477-8939","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"On the potential for discontinuing atovaquone-proguanil (AP) ad-hoc post-exposure and other abbreviated AP-regimens: Pharmacology, pharmacokinetics and perspectives","name":"articletitle","label":"Article Title"},{"value":"Travel Medicine and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmaid.2022.102520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102520"}}